Skip to content
NBlaz – Lifestyle
Author:
Oryzon Genomics, S.A.
ORYZON Initiates Patient Enrollment in IDEAL Phase II Trial of Iadademstat in Essential Thrombocythemia
June 2, 2026
ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026
May 14, 2026
ORYZON to Present Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia at EHA 2026
May 13, 2026
←
Previous Page
1
2